指南与共识睡眠呼吸障碍

成人阻塞性睡眠呼吸暂停肥胖管理指南

Guideline for the Management of Obesity in Adult Patients With Obstructive Sleep Apnea
RSS 订阅 · 指南共识 · 呼吸支持与睡眠 · 2026-02-23

该指南由韩国睡眠与呼吸学会召集多学科专家组制定,采用GRADE方法评价证据并通过共识形成推荐,共提出8条陈述。核心推荐包括将肥胖视为OSA主要危险因素、常规评估超重与肥胖、实施结构化减重干预,生活方式干预不足时推荐GLP-1受体激动剂,非手术治疗无效的重度肥胖建议减重/代谢手术。减重可改善呼吸暂停低通气指数、症状及心脏代谢指标,并可能降低气道正压治疗需求。

要点

  • 肥胖是OSA最重要的可干预危险因素,应常规评估超重与肥胖。
  • 结构化减重以饮食、运动和行为治疗为基础。
  • 生活方式干预不足时推荐GLP-1受体激动剂。

核心结论

  • 体重管理是OSA治疗的核心组成部分,该指南为临床医生提供以肥胖为重点的循证管理策略。

研究设计与样本

  • 韩国睡眠与呼吸学会召集多学科专家组,系统检索主要数据库至2025年,采用GRADE方法评价证据,并通过Evidence-to-Decision框架共识形成推荐。

主要发现

  • 共形成8条陈述,涵盖肥胖作为主要危险因素的识别、超重与肥胖的常规评估、结构化减重、药物治疗和手术治疗的推荐。
  • 减重可改善呼吸暂停低通气指数、症状和心脏代谢标志物,并可能降低气道正压治疗需求。
  • 即使临床改善后仍建议继续随访。

关键数值与推荐

  • 推荐将肥胖视为OSA的主要危险因素,并常规评估超重与肥胖。
  • 推荐通过饮食、运动和行为治疗实施结构化减重。
  • 生活方式干预不足时推荐胰高血糖素样肽-1受体激动剂。
  • 对非手术治疗无反应的重度肥胖建议行减重/代谢手术。
  • 临床改善后仍建议继续随访。

临床怎么用

  • 在OSA管理中应常规评估超重与肥胖,并将体重管理纳入治疗核心。
  • 根据减重干预反应阶梯式选择生活方式干预、GLP-1受体激动剂或减重/代谢手术。
  • 减重治疗应关注AHI、症状及心脏代谢指标的改善,并持续随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clin Exp Otorhinolaryngol. 2026 May;19(2):107-119. doi: 10.21053/ceo.2025-00396. Epub 2026 Feb 23. ABSTRACT OBJECTIVES: Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder that is strongly influenced by obesity, the most important modifiable risk factor. Effective weight management is therefore essential for optimal OSA care. This guideline provides updated, evidence-based recommendations for the evaluation and management of obesity in adults with OSA, incorporating recent advances in lifestyle, pharmacologic, and surgical interventions. METHODS: The Korean Society of Sleep and Breathing convened a multidisciplinary panel. A systematic literature search was performed across major databases through 2025. Evidence was appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, and recommendations were formulated by consensus using the Evidence-to-Decision framework. RESULTS: Eight statements were developed. Key recommendations include recognizing obesity as a major risk factor; routinely assessing overweight and obesity; and implementing structured weight reduction through diet, exercise, and behavioral therapy. Glucagon-like peptide-1 receptor agonists are recommended when lifestyle interventions are insufficient, and bariatric/metabolic surgery is advised for severe obesity unresponsive to nonsurgical treatment. Weight loss improves the apnea-hypopnea index, symptoms, and cardiometabolic markers and may reduce positive airway pressure needs. Continued follow-up is recommended even after clinical improvement. CONCLUSION: Weight management is a core component of OSA treatment. This guideline offers practical, evidence-based strategies to support clinicians in delivering effective, obesity-focused care for adults with OSA. PMID: 41725293 | PMC: PMC13256478 | DOI: 10.21053/ceo.2025-00396

来源:指南共识 · 呼吸支持与睡眠,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 呼吸支持与睡眠:Guideline for the Management of Obesity in Adult Patients With Obstructive Sleep Apnea

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。